Abstract 1766
Background
Despite the availability of improved treatment options in BRAFV600 mutation-positive metastatic melanoma, key questions regarding therapy sequence and duration, tumor dynamics, as well as efficacy in patient subgroups (e.g. brain metastases, concomitant diseases) that were not included in previous phase III clinical trials remain unresolved. Therefore, the objective of this non-interventional prospective study (COMBI-r) was to assess the treatment of a broad patient population in metastatic melanoma with dabrafenib and trametinib in clinical routine.
Methods
Between December 2015 and December 2018, 504 patients at 58 German Skin Cancer Centers were enrolled in COMBI-r. This interims analysis focuses on efficacy (OS, PFS, ORR, DOR) and safety of dabrafenib and trametinib in patients treated for at least 1 year or who have already terminated treatment (approx. 330 patients). During the first year on treatment, visits were scheduled every 3 months, followed by half-yearly visits until end of treatment (EoT), and two follow-up visits at 3 and 6 months.
Results
Efficacy outcomes will be correlated with patient demographics at baseline as well as clinical, laboratory and biological parameters. In addition, patients will be assigned to slow, intermediate and fast tumor dynamic subgroups based on key baseline characteristics previously shown predictive of clinical benefit including tumor stage, organ involvement, therapy line and laboratory markers (S100, LDH).
Conclusions
Data from the COMBI-r interims analysis can provide insights as to whether efficacy and safety demonstrated in clinical trials as well as currently acknowledged predictive factors for clinical benefit and long-term outcomes are transferable to clinical routine. Further, it remains to be evaluated whether other criteria such as tumor dynamics are potentially suitable to predict outcomes in broader and more heterogeneous patient populations in metastatic melanoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Novartis Pharma GmbH.
Funding
Novartis Pharma GmbH.
Disclosure
C. Berking: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Amgen; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : BMS; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Merck Serono; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Novartis; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, institutional grants, personal fees and non-financial support : 4SC; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Non-remunerated activity/ies, personal fees and non-financial support : Pierre Fabre; Honoraria (self), Non-remunerated activity/ies, personal fees and non-financial support : Sanofi-Aventis; Honoraria (self), Non-remunerated activity/ies, institutional grants : Array Pharma; Honoraria (self), Non-remunerated activity/ies, institutional grants : Regeneron; Honoraria (self), Non-remunerated activity/ies, institutional grant and personal fees (member of steering committee) related to the submitted work: Novartis. E. Livingstone: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy: Actelion; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Medac; Travel / Accommodation / Expenses: Pierre Fabre. M. Weichenthal: Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Sun Pharma. K. Wittmann: Full / Part-time employment: Novartis. T. Eigentler: Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Novartis; Advisory / Consultancy: Leo Pharma; Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: MSD. P. Mohr: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: GSK; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi-Aventis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre. F. Kiecker: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre. C. Loquai: Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Sun Pharma. D. Debus: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Amgen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pierre Fabre; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi. R. Gutzmer: Research grant / Funding (self): Pfizer; Research grant / Funding (self): Johnson&Johnson; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Amgen; Advisory / Consultancy, Research grant / Funding (self): MerckSerono; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: GSK; Honoraria (self): MSD; Honoraria (self), Advisory / Consultancy: Almirall-Hermal; Honoraria (self), Advisory / Consultancy: LEO; Honoraria (self), Advisory / Consultancy: Pierre Fabre; Honoraria (self), Advisory / Consultancy: Takeda; Honoraria (self): 4SC; Advisory / Consultancy: Incyte; Advisory / Consultancy: SUN; Honoraria (self): Boehringer Ingelheim; Honoraria (self): AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
3973 - A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck (SCCHN) – OPTIM (AIO-KHT-0117)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract